Janux Therapeutics Incorporated is a biopharma developing therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients with cancer. Its lead TRACTr product candidates target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. The company's EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. Janux Therapeutics was incorporated in 2017 and is headquartered in La Jolla, CA.
What is Janux Therapeutics's quote symbol?
What is the 52 week high and low for Janux Therapeutics (NASDAQ: JANX)?
How much is Janux Therapeutics stock worth today?
How much is Janux Therapeutics's stock price per share?
What is Janux Therapeutics's Market Cap?